Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

  • Showing results for yang, feng chun. Search instead for Yangfeng Chen (1 item)
1.

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.

Guo Y, Zhou Y, Yamatomo S, Yang H, Zhang P, Chen S, Nimer SD, Zhao ZJ, Xu M, Bai J, Yang FC.

Leukemia. 2019 May;33(5):1287-1291. doi: 10.1038/s41375-018-0347-y. Epub 2019 Jan 16. No abstract available.

PMID:
30651633
2.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen DG, Watts J, Vega F, Nimer SD.

Cancer Cell. 2019 Jan 14;35(1):156. doi: 10.1016/j.ccell.2018.12.008. No abstract available.

PMID:
30645972
3.

Cardiac Sca-1+ Cells Are Not Intrinsic Stem Cells for Myocardial Development, Renewal, and Repair.

Zhang L, Sultana N, Yan J, Yang F, Chen F, Chepurko E, Yang FC, Du Q, Zangi L, Xu M, Bu L, Cai CL.

Circulation. 2018 Dec 18;138(25):2919-2930. doi: 10.1161/CIRCULATIONAHA.118.035200.

PMID:
30566018
4.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, McGrew-Jermacowicz A, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen D, Watts J, Vega F, Nimer SD.

Cancer Cell. 2018 Nov 12;34(5):868. doi: 10.1016/j.ccell.2018.10.009. No abstract available.

5.

Chromatin regulator Asxl1 loss and Nf1 haploinsufficiency cooperate to accelerate myeloid malignancy.

Zhang P, He F, Bai J, Yamamoto S, Chen S, Zhang L, Sheng M, Zhang L, Guo Y, Man N, Yang H, Wang S, Cheng T, Nimer SD, Zhou Y, Xu M, Wang QF, Yang FC.

J Clin Invest. 2018 Dec 3;128(12):5383-5398. doi: 10.1172/JCI121366. Epub 2018 Oct 29.

6.

Alteration in the Cytokine Secretion of Bone Marrow Stromal Cells from Patients with Chronic Myelomonocytic Leukemia Contribute to Impaired Hematopoietic Supportive Activity.

Shi H, Wang Y, Li R, Xing W, Yang FC, Bai J, Zhou Y.

Stem Cells Int. 2018 Jul 10;2018:5921392. doi: 10.1155/2018/5921392. eCollection 2018.

7.

Tet2 Regulates Osteoclast Differentiation by Interacting with Runx1 and Maintaining Genomic 5-Hydroxymethylcytosine (5hmC).

Chu Y, Zhao Z, Sant DW, Zhu G, Greenblatt SM, Liu L, Wang J, Cao Z, Tho JC, Chen S, Liu X, Zhang P, Maciejewski JP, Nimer S, Wang G, Yuan W, Yang FC, Xu M.

Genomics Proteomics Bioinformatics. 2018 Jun;16(3):172-186. doi: 10.1016/j.gpb.2018.04.005. Epub 2018 Jun 13.

8.

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.

Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathias V, Jermakowicz AM, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, Liu F, Schurer SC, McCabe MT, Kruger RG, Xu M, Yang FC, Tenen DG, Watts J, Vega F, Nimer SD.

Cancer Cell. 2018 Jun 11;33(6):1111-1127.e5. doi: 10.1016/j.ccell.2018.05.007. Erratum in: Cancer Cell. 2018 Nov 12;34(5):868. Cancer Cell. 2019 Jan 14;35(1):156.

9.

Reduced BAP1 activity prevents ASXL1 truncation-driven myeloid malignancy in vivo.

Guo Y, Yang H, Chen S, Zhang P, Li R, Nimer SD, Harbour JW, Xu M, Yang FC.

Leukemia. 2018 Aug;32(8):1834-1837. doi: 10.1038/s41375-018-0126-9. Epub 2018 Apr 2. No abstract available.

10.

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Li Y, Zhang M, Sheng M, Zhang P, Chen Z, Xing W, Bai J, Cheng T, Yang FC, Zhou Y.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1065-1077. doi: 10.1007/s00432-018-2631-7. Epub 2018 Mar 28.

11.

A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies.

Inoue D, Fujino T, Sheridan P, Zhang YZ, Nagase R, Horikawa S, Li Z, Matsui H, Kanai A, Saika M, Yamaguchi R, Kozuka-Hata H, Kawabata KC, Yokoyama A, Goyama S, Inaba T, Imoto S, Miyano S, Xu M, Yang FC, Oyama M, Kitamura T.

Leukemia. 2018 Jun;32(6):1327-1337. doi: 10.1038/s41375-018-0083-3. Epub 2018 Mar 3.

PMID:
29556021
12.

Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates.

Zhang P, Chen Z, Li R, Guo Y, Shi H, Bai J, Yang H, Sheng M, Li Z, Li Z, Li J, Chen S, Yuan W, Cheng T, Xu M, Zhou Y, Yang FC.

Cell Discov. 2018 Jan 23;4:4. doi: 10.1038/s41421-017-0004-z. eCollection 2018.

13.

TET2 Loss Dysregulates the Behavior of Bone Marrow Mesenchymal Stromal Cells and Accelerates Tet2-/--Driven Myeloid Malignancy Progression.

Li R, Zhou Y, Cao Z, Liu L, Wang J, Chen Z, Xing W, Chen S, Bai J, Yuan W, Cheng T, Xu M, Yang FC, Zhao Z.

Stem Cell Reports. 2018 Jan 9;10(1):166-179. doi: 10.1016/j.stemcr.2017.11.019. Epub 2017 Dec 28.

14.

Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

Yang H, Kurtenbach S, Guo Y, Lohse I, Durante MA, Li J, Li Z, Al-Ali H, Li L, Chen Z, Field MG, Zhang P, Chen S, Yamamoto S, Li Z, Zhou Y, Nimer SD, Harbour JW, Wahlestedt C, Xu M, Yang FC.

Blood. 2018 Jan 18;131(3):328-341. doi: 10.1182/blood-2017-06-789669. Epub 2017 Nov 7.

15.

Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism.

Shao Y, Hernandez-Buquer S, Childress P, Stayrook KR, Alvarez MB, Davis H, Plotkin LI, He Y, Condon KW, Burr DB, Warden SJ, Robling AG, Yang FC, Wek RC, Allen MR, Bidwell JP.

Endocrinology. 2017 Sep 1;158(9):2722-2740. doi: 10.1210/en.2017-00355.

16.

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Chen Y, Pan Y, Guo Y, Zhao W, Ho WT, Wang J, Xu M, Yang FC, Zhao ZJ.

Stem Cell Investig. 2017 Jun 2;4:48. doi: 10.21037/sci.2017.05.04. eCollection 2017. Review.

17.

Loss of Asxl2 leads to myeloid malignancies in mice.

Li J, He F, Zhang P, Chen S, Shi H, Sun Y, Guo Y, Yang H, Man N, Greenblatt S, Li Z, Guo Z, Zhou Y, Wang L, Morey L, Williams S, Chen X, Wang QT, Nimer SD, Yu P, Wang QF, Xu M, Yang FC.

Nat Commun. 2017 Jun 8;8:15456. doi: 10.1038/ncomms15456.

18.

Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells.

Pan F, Wingo TS, Zhao Z, Gao R, Makishima H, Qu G, Lin L, Yu M, Ortega JR, Wang J, Nazha A, Chen L, Yao B, Liu C, Chen S, Weeks O, Ni H, Phillips BL, Huang S, Wang J, He C, Li GM, Radivoyevitch T, Aifantis I, Maciejewski JP, Yang FC, Jin P, Xu M.

Nat Commun. 2017 Apr 25;8:15102. doi: 10.1038/ncomms15102.

19.

PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.

Guo H, Chu Y, Wang L, Chen X, Chen Y, Cheng H, Zhang L, Zhou Y, Yang FC, Cheng T, Xu M, Zhang X, Zhou J, Yuan W.

Int J Cancer. 2017 Jul 15;141(2):324-335. doi: 10.1002/ijc.30739. Epub 2017 May 8.

20.

Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.

Man N, Tan Y, Sun XJ, Liu F, Cheng G, Greenblatt SM, Martinez C, Karl DL, Ando K, Sun M, Hou D, Chen B, Xu M, Yang FC, Chen Z, Chen S, Nimer SD, Wang L.

Blood. 2017 May 18;129(20):2782-2792. doi: 10.1182/blood-2016-10-745034. Epub 2017 Apr 5.

Supplemental Content

Loading ...
Support Center